Pembrolizumab
High Grade Malignant Neoplasm
Kling Biotherapeutics B.V.monoclonal_antibodyPhase 1/2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the High Grade Malignant Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivestim University of Washington | Phase 2 | B |
Cytarabine University of Washington | Phase 2 | B |
Sirolimus University of Washington | Phase 2 | B |
Cladribine University of Washington | Phase 2 | B |
Melphalan University of Washington | Phase 2 | B |
View all 18 →
Same molecule, other indications
Pembrolizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →